A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
To read the full story
Related Article
- Meiji Pharma Rolls Out ATLL Drug Hiyasta in Japan
October 21, 2021
- Veklury’s Normal Distribution in Japan to Start from Oct. 18
September 29, 2021
- Heart Failure Med Verquvo Makes Japan Debut: Bayer
September 16, 2021
- Poxel/Sumitomo Dainippon to Launch Twymeeg on Sept. 16
September 13, 2021
- Alnylam’s 2nd siRNA Therapy Givlaari Hits Japan Market
August 31, 2021
- Otsuka Launches Migraine Drug Ajovy in Japan
August 31, 2021
- Sanwa Kagaku Rolls Out Upasita for Secondary Hyperparathyroidism
August 20, 2021
- 1st Drug for Short Bowel Syndrome Now Available in Japan: Takeda
August 19, 2021
- Eisai Rolls Out Tazverik for EZH2-Positive Follicular Lymphoma
August 17, 2021
- Evrysdi, Aimovig Now Available; Veklury’s Normal Distribution to Start around October
August 13, 2021
- Veklury Distribution via Govt Purchase to Continue for Now: MHLW
August 6, 2021
- Ofev Faces 10%-Plus Cut in Quarterly Price Review; Veklury Gets Listing but No Copay for Now
August 5, 2021
- Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
August 3, 2021
- Japan Approves Verquvo, Evrysdi, 2 CGRP Migraine Meds and More
June 24, 2021
REGULATORY
- OTC-Like Drugs Flagged as Key Agenda Item by CEFP Members
July 29, 2025
- Post-Marketing Oversight and Regulatory Reviews Must Work as One, Says New MHLW Safety Chief
July 29, 2025
- Astellas Employee Did Not Appeal, Prison Sentence Finalized in China
July 29, 2025
- Japan Panel Urges Consolidation of Cancer Surgery, Radiotherapy amid Shrinking Surgeon Workforce
July 29, 2025
- Two Oral Drugs Found to Exceed ADI for Red No. 3, MHLW Reports
July 28, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…